CN103102284A - 4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 - Google Patents
4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 Download PDFInfo
- Publication number
- CN103102284A CN103102284A CN2011103513424A CN201110351342A CN103102284A CN 103102284 A CN103102284 A CN 103102284A CN 2011103513424 A CN2011103513424 A CN 2011103513424A CN 201110351342 A CN201110351342 A CN 201110351342A CN 103102284 A CN103102284 A CN 103102284A
- Authority
- CN
- China
- Prior art keywords
- preparation
- salicylaldoxime
- reaction
- product
- dinitrobenzene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- GQPWUNQVVVBLKM-UHFFFAOYSA-N C(C=1C(O)=CC=CC1)=NO.FC(C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])(F)F Chemical class C(C=1C(O)=CC=CC1)=NO.FC(C1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])(F)F GQPWUNQVVVBLKM-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 5
- 229940126585 therapeutic drug Drugs 0.000 title 1
- 239000000460 chlorine Substances 0.000 claims abstract description 30
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 6
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- -1 salicylaldoxime compound Chemical class 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000000047 product Substances 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 229940073608 benzyl chloride Drugs 0.000 claims description 24
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 14
- 239000002262 Schiff base Substances 0.000 claims description 12
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 11
- 229960004756 ethanol Drugs 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 150000004753 Schiff bases Chemical class 0.000 claims description 10
- 238000001953 recrystallisation Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000010410 layer Substances 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000012044 organic layer Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000006396 nitration reaction Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- GETTZEONDQJALK-UHFFFAOYSA-N trifluorotoluene Substances FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 claims description 3
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 238000007664 blowing Methods 0.000 claims description 3
- 239000003518 caustics Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 230000008034 disappearance Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- CVBDQDVOPGEKFN-UHFFFAOYSA-N 1-chloro-2-nitro-4-(2,2,2-trifluoroethyl)benzene Chemical compound ClC1=C(C=C(CC(F)(F)F)C=C1)[N+](=O)[O-] CVBDQDVOPGEKFN-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 claims description 2
- QULYNCCPRWKEMF-UHFFFAOYSA-N parachlorobenzotrifluoride Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1 QULYNCCPRWKEMF-UHFFFAOYSA-N 0.000 claims description 2
- ORIHZIZPTZTNCU-YVMONPNESA-N salicylaldoxime Chemical compound O\N=C/C1=CC=CC=C1O ORIHZIZPTZTNCU-YVMONPNESA-N 0.000 claims 5
- 239000007795 chemical reaction product Substances 0.000 claims 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 description 25
- 150000001412 amines Chemical group 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 20
- 239000001301 oxygen Substances 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000004243 Tubulin Human genes 0.000 description 8
- 108090000704 Tubulin Proteins 0.000 description 8
- ORIHZIZPTZTNCU-VMPITWQZSA-N 2-[(E)-hydroxyiminomethyl]phenol Chemical class O\N=C\C1=CC=CC=C1O ORIHZIZPTZTNCU-VMPITWQZSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- HFZNWDNDGDEBBV-UHFFFAOYSA-N o-[(2,4-dichlorophenyl)methyl]hydroxylamine;hydrochloride Chemical compound Cl.NOCC1=CC=C(Cl)C=C1Cl HFZNWDNDGDEBBV-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- JHZOXYGFQMROFJ-UHFFFAOYSA-N 3,5-dibromo-2-hydroxybenzaldehyde Chemical compound OC1=C(Br)C=C(Br)C=C1C=O JHZOXYGFQMROFJ-UHFFFAOYSA-N 0.000 description 4
- FABVMBDCVAJXMB-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzaldehyde Chemical compound OC1=C(Cl)C=C(Cl)C=C1C=O FABVMBDCVAJXMB-UHFFFAOYSA-N 0.000 description 4
- MKKSTJKBKNCMRV-UHFFFAOYSA-N 5-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Br)C=C1C=O MKKSTJKBKNCMRV-UHFFFAOYSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910014265 BrCl Inorganic materials 0.000 description 2
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 0 *c1cc(C(F)(F)F)cc(C(C2)C2Cc2c3)c1Oc2c(C=NOCc(cccc1)c1Cl)cc3Cl Chemical compound *c1cc(C(F)(F)F)cc(C(C2)C2Cc2c3)c1Oc2c(C=NOCc(cccc1)c1Cl)cc3Cl 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- BASMANVIUSSIIM-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1Cl BASMANVIUSSIIM-UHFFFAOYSA-N 0.000 description 1
- CGNBQYFXGQHUQP-UHFFFAOYSA-N 2,3-dinitroaniline Chemical class NC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O CGNBQYFXGQHUQP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- WWTFFBZRBMVCBR-JBQSXSRFSA-N O=Nc1cc(C(F)(F)F)cc(N=O)c1Oc(c(Cl)c1)c(/C=N/OCc(c(Cl)c2)ccc2Cl)cc1Cl Chemical compound O=Nc1cc(C(F)(F)F)cc(N=O)c1Oc(c(Cl)c1)c(/C=N/OCc(c(Cl)c2)ccc2Cl)cc1Cl WWTFFBZRBMVCBR-JBQSXSRFSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- VUZQUGQENZBEMD-BRJLIKDPSA-N [O-][N+](c1cc(C(F)(F)F)cc([N+]([O-])=O)c1Oc1c(/C=N/OCc2ccccc2)cccc1)=O Chemical compound [O-][N+](c1cc(C(F)(F)F)cc([N+]([O-])=O)c1Oc1c(/C=N/OCc2ccccc2)cccc1)=O VUZQUGQENZBEMD-BRJLIKDPSA-N 0.000 description 1
- KODGRBDAJZWOPD-HIUVJMHLSA-N [O-][NH+]1[ClH]c2cc(Cl)cc(/C=N/OCc(cccc3)c3F)c2Oc2c1cc(C(F)(F)F)cc2[N+]([O-])=O Chemical compound [O-][NH+]1[ClH]c2cc(Cl)cc(/C=N/OCc(cccc3)c3F)c2Oc2c1cc(C(F)(F)F)cc2[N+]([O-])=O KODGRBDAJZWOPD-HIUVJMHLSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000033600 microtubule polymerization or depolymerization Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003219 pyrazolines Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一类4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物,其特征是它有如下通式:
Description
技术领域
本发明涉及水杨醛肟类化合物及其制备方法与抗肿瘤药物。
背景技术
癌症是严重威胁人类健康的主要疾病之一。细胞增殖与凋亡的非平衡匹配及其转移扩散是恶性肿瘤发生的基础。而微管--细胞骨架的主要成分-在细胞活动方面发挥着重要的作用,其在细胞有丝***过程中具有牵引染色体的作用。正常状态下,微管处于微管蛋白二聚体的‘聚合-解聚’动态平衡中。平衡破坏将阻止细胞周期的正常进行,引起细胞凋亡。故而,以微管蛋白为化疗作用靶点是肿瘤疾病治疗的重要途径和手段。
研究发现,一些含希夫碱C=N基团的药物能够结合微管蛋白,影响微管聚合或者解聚从而阻止细胞周期,导致细胞凋亡。例如,氨基咪唑希夫碱衍生物(有效抑制人胃癌细胞NUGC-3以及鼠白血病细胞P388增值)、三氮唑希夫碱衍生物(显著抑制人肝癌细胞BEL-7402、SMMC-7721、BEL-7402增值)、希夫碱配合物及阿苯达唑等均具有明显抗微管蛋白活性,并最终阻滞细胞周期进程,诱导细胞凋亡。先前研究表明,醛取代基抗癌效应优于胺取代基,水杨醛类希夫碱优于其他醛类。另外,二硝基苯胺类化合物主要通过对真核细胞中a-和b-微管蛋白基因的干扰表达,阻碍微管蛋白聚合作用,从而诱导细胞凋亡。
前期工作中,我们已经合成了一批各种取代基的水杨醛系列希夫碱,并测试了其生物活性,此文中,这些水杨醛希夫碱和二硝基三氟甲苯类化合物通过取代反应,形成了一系列的未经报道的新化合物。正是基于以上多种基团的药效及其配伍研究,推断这些新化合物可能体现出希夫碱和二硝基三氟甲苯类化合物在抗肿瘤中的协同性。我们测试了这批化合物的活性,并发现其对MCF7、HepG2、A549具有良好的抑制作用,且能与微管蛋白作用从而抑制细胞周期,引起细胞凋亡。
发明内容
本发明的目的在于提供一类新型水杨醛肟类化合物以及它们的制备方法与用途。本发明的技术方案如下:
1.一类水杨醛肟衍生物,其特征是它有如下通式:
结构式中R1为:氢、5-氯、3,5-二氯、5-溴、3,5-二溴。
R2为:氢、2-氟、2-氯、2,4-二氯。
2.一种制备上述的水杨醛肟类衍生物的方法,它由下列步骤组成:
步骤1.制备苄氧胺盐酸盐:
(1)邻苯二甲酸酐保护的羟胺合成
具体合成方法:在配有机械搅拌器,回流冷凝管的500ml三颈圆底烧瓶中,分别加入0.2摩尔的两种原料,在向体系内添加150ml吡啶,于80℃反应过夜(TLC检测反应进行程度)。待反应完全,加入大量的水中,析出产物后用氯仿溶解后水洗活性炭脱色,无水硫酸镁干燥,滤除干燥剂,蒸干溶剂后得产物。
(2)羟胺取代氯苄反应
于250ml三颈圆底烧瓶中,加入0.2mol保护的羟胺,再加入2mol/L氢氧化钠水溶液,至固体反应完全,控制ph在8-9之间,加入摩尔比为5%量的苄基三乙基氯化铵,再滴加氯苄的氯仿溶液,至反应完全,分出有机层,水层萃取三次后合并有机层,无水硫酸镁干燥,旋干溶剂得粗品。
(3)脱保护反应
取一250ml三颈圆底烧瓶,称取第二步产物20g,再加入150ml乙醇,使样品完全溶解后,冷却至0℃,向体系内滴加水合肼,至原料点消失,产物经柱层析分离备用。
(4)成盐反应
将苄氧胺溶解在二氯甲烷中,冰盐浴冷却至-5℃左右,并通入干燥的氯化氢(实验室自制),控制气体流速,尾气用浓氢氧化钠溶液吸收,通气体至产物全部析出。用氮气吹尽氯化氢后过滤即可获得苄氧胺盐酸盐。
步骤2.制备希夫碱(水杨醛肟):
将取代基苄氧胺盐酸盐(5.0mmol),溶于无水乙醇,缓慢滴入等当量三乙胺(5.0mmol),再加入取代基水杨醛(5.0mmol),磁搅拌,常温反应0.5h(TLC检测反应进行程度),产物以固体析出。反应结束后抽滤,并以无水乙醇冲洗固体物3次,干燥得取代基希夫碱(水杨醛肟)。用无水乙醇将产物重结晶。
步骤3.制备4-氯-3,5-二硝基三氟甲苯:
制备4-氯-3,5-二硝基三氟甲苯
将混酸加入装有4-氯-3-硝基三氟甲苯的圆底烧瓶中(>2.5∶1),磁搅拌,于115℃反应4h(TLC检测反应进行程度)。待反应结束,自然冷却,静置分层,分液弃去下层棕黄色酸层,再用乙酸乙酯与饱和碳酸氢钠洗涤萃取3次,旋转蒸发仪抽干萃取液,所得固体用乙醇重结晶。
步骤4.合成4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物
于50ml烧瓶中加入4mmol K2CO3,以及2mmol取代基希夫碱,2mmol4-氯-3,5-二硝基三氟甲苯,并溶解于20mml无水乙醇中,磁搅拌,常温反应1h(TLC检测)。待反应结束,用真空将溶剂抽干,将烧瓶中残余固体 溶于30ml乙酸乙酯中,用饱和食盐水洗涤萃取3次。真空抽干萃取液,得到残余固体用乙醇重结晶,得到最终产物。
本发明的4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物具有抑制MCF-7、A549、HepG2细胞增殖的作用。因此本发明的4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物可做潜在的抗肿瘤药物。
具体实施方式
实施例一:5-氯-2(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氯苄基)肟(化合物1)的制备
在配有机械搅拌器,回流冷凝管的500ml三颈圆底烧瓶中,分别加入0.2mol的邻苯二甲酸酐与水合肼,并向体系内添加150ml吡啶,于80℃反应过夜(TLC检测反应进行程度)。待反应完全,加入大量的水中,析出产物后用氯仿溶解后水洗活性炭脱色,无水硫酸镁干燥,滤除干燥剂,蒸干溶剂后得产物a。取0.2mol产物a于圆底烧瓶,再加入2mol/L氢氧化钠水溶液,至固体反应完全,控制ph在8-9之间,加入摩尔比为5%量的苄基三乙基氯化铵,再滴加1-氯-2-(氯甲基)苯(即取代基苄氯)的氯仿溶液,至反应完全,分出有机层,水层萃取三次后合并有机层,无水硫酸镁干燥,旋干溶剂得粗品b。称取第二步产物b 20g,再加入150ml乙醇,使样品完全溶解后,冷却至0℃,向体系内滴加水合肼,至原料点消失,产物c经柱层析分离备用。将产物c溶解在二氯甲烷中,冰盐浴冷却至-5℃左右,并通入干燥的氯化氢(实验室自制),控制气体流速,尾气用浓氢氧化钠溶液吸收,通气体至产物全部析出。用氮气吹尽氯化氢后过滤即可获得产物d 5-氯取代基苄氧胺盐酸盐。将2-氯苄氧胺盐酸盐(5.0mmol),溶于无水乙醇,缓慢滴入等当量三乙胺(5.0mmol),再加入取代基水杨醛(5.0mmol),磁搅拌, 常温反应0.5h(TLC检测反应进行程度),产物以固体析出。反应结束后抽滤,并以无水乙醇冲洗固体物3次,纯化、干燥得产物e。
将95%的发烟硝酸与98%的浓硫酸至少以1∶1配成混酸,在50-55℃下,缓慢滴加于装有4-氯三氟甲苯的圆底烧瓶中(>1∶1),磁搅拌,控制反应温度,待滴加完毕,温度保持0.5h,后升至70℃左右继续反应大约2h(TLC检测反应进行程度)。待反应结束,自然冷却,静置分层,分液弃去下层棕黄色酸层,再用乙酸乙酯与饱和碳酸氢钠洗涤萃取3次,旋转蒸发仪抽干萃取液,所得固体用乙醇重结晶,得到产物f。同上,将混酸加入装有产物f的圆底烧瓶中(>2.5∶1),磁搅拌,于115℃反应4h(TLC检测反应进行程度)。待反应结束,自然冷却,静置分层,分液弃去下层棕黄色酸层,再用乙酸乙酯与饱和碳酸氢钠洗涤萃取3次,旋转蒸发仪抽干萃取液,所得固体用乙醇重结晶,得到g产物。
于50ml烧瓶中加入4mmol K2CO3,以及2mmol产物e,2mmol产物g,并溶解于20mml无水乙醇中,磁搅拌,常温反应1h(TLC检测)。待反应结束,用真空将溶剂抽干,将烧瓶中残余固体溶于30ml乙酸乙酯中,用饱和食盐水洗涤萃取3次。真空抽干萃取液,得到残余固体用乙醇重结晶,得淡黄色固体。产率:97%,mp:159-160℃;1H NMR(CDCl3,300MHz);5.3870(s,2H);6.4478(d,J=8.79HZ,1H);7.1756-7.2134(m,1H);7.2591-7.3189(m,2H);3.7316(t,J=4.5750HZ,1H);7.4969(t,J=6.1650HZ,1H);7.9267(d,J=2.5500HZ,1H);8.4661(s,2H);8.5344(s,1H).ESI-MS:530.24(C21H13Cl2F3N3O6[M+H]+).Anal.Calcd for C21H12Cl2F3N3O6:C,47.57;H,2.28;Cl,13.37;F,10.75;N,7.92;O,18.10.Found:C,47.11;H,2.83;N,7.34.
实施例二:5-氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2,4-二氯苄基)肟(化合物2)的制备
制备方法同实施例一。5-氯水杨醛不变,2,4-二氯苄氧胺盐酸盐代替例一中的2- 氯苄氧胺盐酸盐。得到淡黄色固体。产率:85%,mp:166-167℃;1HNMR(CDCl3,300MHz):6.4487(d,J=8.97HZ,1H);7.1768-7.2152(m,1H);7.2603-7.3012(m,3H);7.3865-7.4170(m,1H);7.4810-7.6066(m,1H);7.9279(d,J=0.15,1H);8.4637(s,2H);8.5344(s,1H).ESI-MS:564.68(C21H12Cl3F3N3O6[M+H]+).Anal.Calcd for C21H11Cl3F3N3O6:C,44.67;H,1.96;Cl,18.84;F,10.09;N,7.44;O,17.00Found:C,44.69;H,1.93;N,7.44.
实施例三:3,5-二氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氯苄基)肟(化合物3)的制备
制备方法同实施例一。以3,5-二氯水杨醛代替例一中的5-氯水杨醛,2-氯苄氧胺盐酸盐不变。得到黄色固体。White powder,59%,mp154-156℃;1HNMR(CDCl3300MHz):5.3724(s,2H);7.2640-7.2945(m,1H);7.3299(d,J=2.55HZ,1H);7.3871-7.4176(m,1H);7.4420-7.5103(m,1H);7.8267(d,J=2.55HZ,1H);8.2993(s,2H);8.4423(s,1H).ESI-MS:564.68(C21H12Cl3F3N3O6,[M+H]+).Anal.Calcd forC21H11Cl3F3N3O6:C,44.67;H,1.96;Cl,18.84;F,10.09;N,7.44;O,17.00.Found:C,44.65;H,1.99;N,7.42.
实施例四:3,5-二氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2,4-二氯苄基)肟(化合物4)的制备
制备方法同实施例一。以3,5-二氯水杨醛代替例一中的5-氯水杨醛,以2,4-二氯苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到淡黄色固体。产率:75%,mp170-171℃;1HNMR(CDCl3,300MHz):5.2964(d,J=9.69HZ,2H);7.2640-7.2945(m,1H);7.3299(d,J=2.55HZ,1H);7.3871-7.4420(m,1H);7.4591-7.5103(m,1H);7.7960(d,J=2.55HZ,1H);8.2893(s,2H);8.4423(s,1H).ESI-MS:599.13(C21H11Cl4F3N3O6 [M+H]+).Anal.Calcd for C21H10Cl4F3N3O6:C,42.10;H,1.68;Cl,23.67;F,9.51;N,7.01;O,16.02.Found:C,42.08;H,1.69;N,7.61.
实施例五:5-溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氯苄基)肟
(化合物5)的制备
制备方法同实施例一。以5-溴水杨醛代替例一中的5-氯水杨醛,2-氯苄氧胺盐酸盐不变。得到淡黄色固体。产率:68%,mp:108-109℃;1HNMR(CDCl3,300MHz):5.3905(s,2H);6.3903(d,J=8.85HZ,1H);7.2607-7.3028(m,2H);7.3223-7.3601(m,1H);7.4005(t,J=4.575HZ,1H);7.4915(d,J=6.39,1H);8.0767(d,J=2.40HZ,1H);8.4696(s,2H);8.5287(s,1H).ESI-MS:574.69(C21H13BrClF3N3O6[M+H]+).Anal.Calcd forC21H12BrClF3N3O6:C,43.89;H,2.10;Br,13.90;Cl,6.17;F,9.92;N,7.31;O,16.70.Found:C,43.79;H,2.15;N,7.38.
实施例六:5-溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2,4-二氯苄基)肟(化合物6)的制备
制备方法同实施例一。以5-溴水杨醛代替例一中的5-氯水杨醛,以2,4-二氯苄氧胺盐酸盐代替2-氯苄氧胺盐酸盐。得到淡黄色固体。产率:73%,mp:117-125℃;1HNMR(CDCl3,300MHz):5.3319(s,2H);6.3933(d,J=8.79HZ,1H);7.2775(d,J=10.05,1H);7.3283-7.3655(m,1H);7.4297(t,J=7.68HZ,2H);8.0489(d,J=3.12,1H);8.43954(d,J=11.88HZ,3H).ESI-MS:609.13(C21H12BrCl2F3N3O6[M+H]+).Anal.Calcd for C21H11BrCl2F3N3O6:C,41.41;H,1.82;Br,13.12;Cl,11.64;F,9.36;N,6.90;O,15.76.Found:C,41.44;H,1.78;N,6.97.
实施例七:3,5-二溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氯苄 基)肟(化合物7)的制备
制备方法同实施例一。以3,5-二溴水杨醛代替例一中的5-氯水杨醛,2-氯苄氧胺盐酸盐不变。得到淡黄色固体。产率:59%,mp:112-114℃;1H NMR(CDCl3,300MHz):5.3481(d,J=9.51,2H);6.4526(d,J=8.76HZ,1H);7.1847-7.2225(m,1H);7.2813(t,J=5.04,1H);7.4284(t,3.93HZ,2H);7.9014(d,J=2.73HZ,1H);8.4673(s,2H);8.5216(s,1H).ESI-MS:653.58(C21H12Br2ClF3N3O6[M+H]+).Anal.Calcd for C21H11Br2ClF3N3O6:C,38.59;H,1.70;Br,24.45;Cl,5.42;F,8.72;N,6.43;O,14.69.Found:C,38.63;H,1.56;N,6.37.
实施例八:3,5-二溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2,4-二氯苄基)肟(化合物8)的制备
制备方法同实施例一。以3,5-二溴水杨醛代替例一中的5-氯水杨醛,以2,4-二氯苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:66%,mp:157-159℃;1HNMR(CDCl3,300MHz):7.2439(s,1H);7.3644(t,J=9.615HZ,1H);7.4133-7.4414(m,2H);7.6399(t,J=2.28,2H);7.9706(d,J=2.19,1H);8.2717(s,2H);8.4052(s,1H).ESI-MS:688.03(C21H11Br2Cl2F3N3O6[M+H]+).Anal.Calcd for C21H10Br2Cl2F3N3O6:C,36.66;H,1.46;Br,23.23;Cl,10.31;F,8.28;N,6.11;O,13.95.Found:C,36.73;H,1.48;N,6.07.
实施例九:2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氯苄基)肟(化合物9)的制备
制备方法同实施例一。以水杨醛代替例一中的5-氯水杨醛,2-氯苄氧胺盐酸盐不变。得到黄色固体。产率:58%,mp:141-142℃;1H NMR(CDCl3,300MHz):6.4971-6.5276(m,1H);7.1402-7.2262(m,1H);7.2329-7.2652(m,1H);7.2744-7.2896(m,2H);7.2963-7.3213(m,2H);7.3865-7.4170(m,1H);7.5084-7.5395(m,1H);7.8693-7.9669(m,1H);8.4564(m,2H);8.6271(m,1H).ESI-MS:495.79(C21H14ClF3N3O6[M+H]+).Anal.Calcd for C21H13ClF3N3O6:C,50.87;H,2.64;Cl,7.15;F,11.50;N,8.48;O,19.36.Found:C,50.78;H,2.69;N,8.63.
实施例十:2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2,4-二氯苄基)肟(化合物10)的制备
制备方法同实施例一。以水杨醛代替例一中的5-氯水杨醛,以2,4-二氯苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到淡黄色固体。产率:67%,mp:142-143℃;1HNMR(CDCl3,300MHz):5.3447(d,J=7.02,2H);6.5002-6.5306(m,1H);7.1427-7.2335(m,1H);7.2396-7.2670(m,1H);7.2737-7.2945(m,1H);7.4206(d,J=2.19HZ,1H);7.4582(d,J=8.25HZ,1H);7.9096-7.9413(m,1H);8.4612(s,2H);8.6149(s,1H).ESI-MS:530.24(C21H13Cl2F3N3O6[M+H]+).Anal.Calcd for C21H12Cl2F3N3O6:C,47.57;H,2.28;Cl,13.37;F,10.75;N,7.92;O,18.10.Found:C,47.55;H,2.31;N,7.90.
实施例十一:5-氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(苄基)肟(化合物11)的制备
制备方法同实施例一。5-氯水杨醛不变,以苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:89%,mp:143-146℃;1H NMR(CDCl3,300MHz):5.2450(s,2H);7.0765(d,J=9.03,1H);7.3652-7.4450(m,6H);7.7633(d,J=2.55,1H);8.4692(s,1H);8.9398(s,2H);ESI-MS:495.79(C21H14ClF3N3O6[M+H]+).Anal.Calcd forC21H13ClF3N3O6:C,50.87;H,2.64;Cl,7.15;F,11.50;N,8.48;O,19.36.Found:C,50.79;H,2.64;N,8.43.
实施例十二:5-氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氟苄基)肟(化合物12)的制备
制备方法同实施例一。5-氯水杨醛不变,以2-氟苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色粉末。产率:78%,mp:122-126℃;1HNMR(CDCl3,300MHz):5.2925(s,2H);7.0760(d,J=8.97,1H);7.2055-7.2670(m,2H);7.3914-7.4481(m,2H);5.2060(t,J=7.59HZ,1H);7.755(d,J=2.76HZ,1H);8.4576(s,1H);8.9367(s,2H).ESI-MS:513.78(C21H13ClF4N3O6[M+H]+).Anal.CalcdforC21H12ClF4N3O6:C,49.09;H,2.35;Cl,6.90;F,14.79;N,8.18;O,18.68.Found:C,49.11;H,2.33;N,8.03.
实施例十三:5-溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(苄基)肟(化合物13)的制备
制备方法同实施例一。以5-溴水杨醛代替例一中的5-氯水杨醛,一苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色粉末。产率:92%,mp:130-139℃;1HNMR(CDCl3,300MHz):7.2575(d,J=19.92HZ,2H);6.9994(d,J=8.76HZ,1H);7.3310-7.4402(m,5H);7.5176-7.5554(m,1H);7.8882(d,J=2.58,1H);8.4588(s,1H);8.9294(s,2H).ESI-MS:540.24(C21H14BrF3N3O6[M+H]+).Anal.Calcd for C21H13BrF3N3O6:C,46.69;H,2.43;Br,14.79;F,10.55;N,7.78;O,17.77.Found:C,46.70;H,2.46;N,7.73.
实施例十四:5-溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氟苄基)肟(化合物14)的制备
制备方法同实施例一。以5-溴水杨醛代替例一中的5-氯水杨醛,以2-氟苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到淡黄色固体。White powder,产率:92%,mp:121-128℃;1HNMR(CDCl3,300MHz):5.3476(t,J=10.515HZ,2H);6.3935(d,J=8.76HZ,1H);7.0726(m,1H);7.1893(d,J=7.5HZ,1H);7.3176-7.3682(m,2H);7.4828(t,J=7.305HZ,1H);8.0858(d,J=2.55HZ,1H);8.4834(d,J=3.12HZ,3H).ESI-MS:558.23(C21H13BrF4N3O6[M+H]+).Anal.Calcd for C21H12BrF4N3O6:C,45.18;H,2.17;Br,14.31;F,13.61;N,7.53;O,17.20.Found:C,45.28;H,2,15;N,7.57.
实施例十五:3,5-二氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(苄基)肟(化合物15)的制备
制备方法同实施例一。以3,5-二氯水杨醛代替例一中的5-氯水杨醛,以苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:79%,mp:139-145℃;1HNMR(CDCl3,300MHz):5.2828(d,J=10.62HZ,2H);6.3807(d,J=8.76HZ,1H);7.2591-7.4438(m,5H);8.0836(d,J=2.400HZ,1H);8.4713(d,J=6.0600HZ,3H).ESI-MS:530.24(C21H13Cl2F3N3O6[M+H]+).Anal.Calcd for C21H12Cl2F3N3O6:C,47.57;H,2.28;Cl,13.37;F,10.75;N,7.92;O,18.10.Found:C,47.54;H,2.31;N,7.89.
实施例十六:3,5-二氯-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氟苄基)肟(化合物16)的制备
制备方法同实施例一。以3,5-二氯水杨醛代替例一中的5-氯水杨醛,以2-氟苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:93%,mp:111-112℃;1HNMR(CDCl3,300MHz):5.2820(t,J=10.095HZ,2H);7.0579-7.1335(m,1H);7.1716(d,J=7.5HZ,1H);7.2945-7.3707(m,2H);7.4391(t,J=7.395HZ,1H);7.8249(d,J=2.55HZ,1H);8.2881(s,2H);8.3917(s,1H).ESI-MS:548.23(C21H11Cl3F4N3O6[M+H]+).Anal.Calcd for C21H11Cl2F4N3O6:C,46.01;H,2.02;Cl,12.93;F,13.86;N,7.66;O,17.51.Found:C,46.01;H,2.01;N,7.66
实施例十七:3,5-二溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(苄基)肟(化合物17)的制备
制备方法同实施例一。以3,5-二溴水杨醛代替例一中的5-氯水杨醛,以苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到淡黄色固体。产率:89%,mp:123-124℃;1HNMR(CDCl3,300MHz):5.1225(s,2H);7.2823-7.3725(m,5H);7.9041(d,J=2.19HZ,1H);8.0648(d,J=2.4HZ,1H);8.4100(s,1H);8.8307(s,2H).ESI-MS:619.14(C21H13Br2F3N3O6[M+H]+).Anal.Calcd for C21H12Br2F3N3O6:C,40.74;H,1.95;Br,25.81;F,9.21;N,6.79;O,15.50.Found:C,40.73;H,1.99;N,6.76.
实施例十八:3,5-二溴-2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氟苄基)肟(化合物18)的制备
制备方法同实施例一。以3,5-二溴水杨醛代替例一中的5-氯水杨醛,以2-氟苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:98%,mp:94-96℃;1HNMR(CDCl3,300MHz):5.2316(d,J=37.32HZ,2H);7.1512-7.2298(m,2H);7.3615-7.4328(m,2H);7.9489(d,J=2.37HZ,1H);8.0708(d,J=2.40HZ,1H);8.4094(s,1H);8.8252(s,2H).ESI-MS:637.13(C21H12Br2F4N3O6[M+H]+).Anal.CalcdforC21H11Br2F4N3O6:C,39.59;H,1.74;Br,25.08;F,11.93;N,6.60;O,15.07.Found:C,39.61;H,1.74;N,6.63.
实施例十九:2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(苄基)肟(化合物19)的制备
制备方法同实施例一。以水杨醛代替例一中的5-氯水杨醛,以苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:95%,mp:92-94℃;
1HNMR(CDCl3,300MHz):5.2267(s,2H);6.9723(d,J=8.22HZ,1H);7.2081(t,J=7.59HZ,1H);7.3225-7.4493(m,6H);7.8098(t,J=3.84HZ,1H);8.5124(s,1H);8.9276(s,2H).ESI-MS:461.35(C21H15F3N3O6[M+H]+).Anal.Calcd for C21H14F3N3O6:C,54.67;H,3.06;F,12.35;N,9.11;O,20.81.Found:C,54.64;H,3.09;N,9.13.
实施例二十:2-(2,6-二硝基-4-(三氟甲苯)苯氧基)苯甲醛-O-(2-氟苄基)肟(化合物20)的制备
制备方法同实施例一。以水杨醛代替例一中的5-氯水杨醛,以2-氟苄氧胺盐酸盐代替例一中的2-氯苄氧胺盐酸盐。得到黄色固体。产率:98%,mp:98-100℃;
1HNMR(CDCl3,300MHz):5.3523(d,J=8.40HZ,2H);6.5023(d,J=8.22HZ,1H);7.4279(t,J=9.135HZ,1H);7.1699(t,J=7.05HZ,2H);7.2256-7.2737(m,1H);7.2841-7.3640(m,1H);7.4749-7.5243(m,1H);7.9400-7.9717(m,1H);8.4533(s,2H);8.5783(s,1H).ESI-MS:479.34(C21H14F4N3O6[M+H]+).Anal.Calcd for C21H13F4N3O6:C,52.62;H,2.73;F,15.85;N,8.77;O,20.03.Found:C,52.52;H,2.70;N,8.73.
实施例二十一:吡唑啉衍生物对肿瘤抑制活性研究
采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法来测定水杨醛肟类化合物对MCF7、HepG2、A549及anti-tubulin半抑制浓度,即IC50。
(1)培养液(每升)的配制:①悬浮细胞:RPMI-1640培养粉一袋(10.4g),新生牛血清100ml,青霉素溶液(20万U/ml)0.5ml,链霉素溶液(20万U/ml)0.5ml,加三蒸水溶解后,用5.6%的NaHCO3溶液调PH值至7.2-7.4,最后定容至1000ml。过滤灭菌。②贴壁细胞:同上,再加入NaHCO32.00g,HEPES 2.38g。
(2)D-Hanks缓冲液(每升)的配制:NaCl 8.00g,KCl 0.40g,Na2HPO4·12H2O 0.06g,KH2PO40.06g,NaHCO30.35g。高压灭菌。
(3)胰蛋白酶液的配制:利用D-Hanks缓冲液配成浓度为0.5%胰蛋白酶 液。过滤除菌。
(4)实验药液的配制:将测试样品用少量的三蒸水溶解配成储备液,一般按实验最高浓度的10倍配制储备液。根据化合物溶解性不同,可用三蒸水直接溶解,或用少量DMSO助溶,再加三蒸水溶解。DMSO在培养液中的浓度不宜过大,加药后的每孔细胞悬液中DMSO的终浓度一般不超过0.05%-0.1%。储备液保存于-20℃冰箱中备用。
(5)细胞培养:为贴壁生长细胞,常规培养于DMEM或者RPMI-1640培养液内(含10%小牛血清),置37℃、5%CO2培养箱中培养,每隔3-4天传代一次。传代时先弃去原培养液,再用D-Hanks缓冲液洗涤;然后用0.5%胰蛋白酶消化30秒左右,加入少量新鲜培养液终止消化;吹打,使贴壁细胞从培养瓶壁上脱落下来;移取适量至新鲜培养瓶中,再补充新鲜培养液至原体积(培养液体积约为培养瓶容量的1/10)。
(6)细胞孵育:取对数生长期的上述肿瘤细胞,调细胞悬液浓度为2×104个/ml。在96孔培养板中每孔加细胞悬液100μl,置37℃,5%CO2培养箱中培养24h。培养24h后,分别按设计加入药液。
(7)加药:将测试药液按照最终浓度的浓度梯度分别加入到各个孔中,每个浓度设6个平行孔。实验分为药物试验组(分别加入不同浓度的测试药)、对照组(只加培养液和细胞,不加测试药)和空白组(只加培养液,不加细胞和测试药)。将加药后的96孔板置于37℃,5%CO2培养箱中培养48h。
(8)存活细胞的测定:在培养了48h后的96孔板中,每孔加MTT 40μl(用40μl PBS配成2.5mg/ml的MTT)。在37℃放置4h后,移去上清液。每孔加100μl提取液(10%SDS-5%异丁醇-0.01M HCl)。37℃孵育过夜,最后,利用自动酶标仪在570nm波长处检测各孔的光密度(OD值)。
抑制率的计算:细胞生长的抑制率按照下列公式计算:
生长抑制率=(1-存活率)×100%=[1-(OD实验-OD空白)/(OD对照-OD空白)]×100%(OD实验表示测试药物组的平均光密度,OD对照表示对照组的平均光密度,OD空白表示对照组的平均光密度)。
半数抑制浓度(IC50)定义为当50%的肿瘤细胞存活时的药物浓度。根据测定的光密度(OD值),制作细胞生长抑制率的标准曲线,在标准曲线上求得其 对应的药物浓度。
测得的IC50见表1所示
(9)药物对微管蛋白聚合影响的测定
将不同浓度的药与10μM溶于谷氨酸缓冲液的牛脑微管蛋白溶液30℃预培养,然后冷却到0℃.加GTP,混合物转移到0℃预冷的分光光度计的玻璃管。升温到30℃,依靠浊度计法可以观察到微管蛋白的装配。IC50的计算方法是,20min孵育后,抑制微管蛋白装配达50%程度时所加的药物的浓度。
测得的IC50见表1所示
Compound 1-20的通式
表1.Compound 1-20对MCF7、HepG2、A549细胞增值和微管蛋白的抑制作用
Claims (4)
2.一种制备上述的4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的方法,它由下列步骤组成:
步骤1.制备苄氧胺盐酸盐:
(1)邻苯二甲酸酐保护的羟胺合成
在配有机械搅拌器,回流冷凝管的500ml三颈圆底烧瓶中,分别加入0.2mol的两种原料,在向体系内添加150ml吡啶,于80℃反应过夜(TLC检测反应进行程度)。待反应完全,加入大量的水中,析出产物后用氯仿溶解后水洗活性炭脱色,无水硫酸镁干燥,滤除干燥剂,蒸干溶剂后得产物。
(2)羟胺取代氯苄反应
于250ml三颈圆底烧瓶中,加入0.2mol保护的羟胺,再加入2mol/L氢氧化钠水溶液,至固体反应完全,控制pH在8-9之间,加入摩尔比为5%量的苄基三乙基氯化铵,再滴加氯苄的氯仿溶液,至反应完全,分出有机层,水层萃取三次后合并有机层,无水硫酸镁干燥,旋干溶剂得粗品。
(3)脱保护反应
取一250ml三颈圆底烧瓶,称取第二步产物20g,再加入150ml乙醇,使样品完全溶解后,冷却至0℃,向体系内滴加水合肼,至原料点消失,产物经柱层析分离备用。
(4)成盐反应
将苄氧胺溶解在二氯甲烷中,冰盐浴冷却至-5℃左右,并通入干燥的氯化氢(实验室自制),控制气体流速,尾气用浓氢氧化钠溶液吸收,通气体至产物全部析出。用氮气吹尽氯化氢后过滤即可获得苄氧胺盐酸盐。
步骤2.制备4-氯-3,5-二硝基三氟甲苯:
制备4-氯-3-硝基三氟甲苯
将95%的发烟硝酸与98%的浓硫酸至少以1∶1配成混酸,在50-55℃下,缓慢滴加于装有4-氯三氟甲苯的圆底烧瓶中(>1∶1),磁搅拌,控制反应温度,待滴加完毕,温度保持0.5h,后升至70℃左右继续反应大约2h(TLC检测反应进行程度)。待反应结束,自然冷却,静置分层,分液弃去下层棕黄色酸层,再用乙酸乙酯与饱和碳酸氢钠洗涤萃取3次,旋转蒸发仪抽干萃取液,所得固体用乙醇重结晶,得到最终产物。
步骤3.制备希夫碱(水杨醛肟):
将取代基苄氧胺盐酸盐(5.0mmol),溶于无水乙醇,缓慢滴入等当量三乙胺(5.0mmol),再加入取代基水杨醛(5.0mmol),磁搅拌,常温反应0.5h(TLC检测反应进行程度),产物以固体析出。反应结束后抽滤,并以无水乙醇冲洗固体物3次,干燥得取代基希夫碱(水杨醛肟)。用无水乙醇将产物重结晶。
步骤4.制备4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物
类似(1)中,将混酸加入装有4-氯-3-硝基三氟甲苯的圆底烧瓶中(>2.5∶1),磁搅拌,于115℃反应4h(TLC检测反应进行程度)。待反应结束,自然冷却,静置分层,分液弃去下层棕黄色酸层,再用乙酸乙酯与饱和碳酸氢钠洗涤萃取3次,旋转蒸发仪抽干萃取液,所得固体用乙醇重结晶,得到最终产物。
步骤.合成水杨醛肟终产物
于50ml烧瓶中加入4mmol K2CO3,以及2mmol取代基希夫碱,2mmol 4-氯-3,5-二硝基三氟甲苯,并溶解于20mml无水乙醇中,磁搅拌,常温反应1h(TLC检测)。待反应结束,用真空将溶剂抽干,将烧瓶中残余固体溶于30ml乙酸乙酯中,用饱和食盐水洗涤萃取3次。真空抽干萃取液,得到残余固体用乙醇重结晶,得到最终产物。
3.权利要求2所述的水杨醛肟类衍生物的制备方法。
4.权利要求1所述的水杨醛肟类衍生物在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103513424A CN103102284A (zh) | 2011-11-09 | 2011-11-09 | 4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011103513424A CN103102284A (zh) | 2011-11-09 | 2011-11-09 | 4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103102284A true CN103102284A (zh) | 2013-05-15 |
Family
ID=48310518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011103513424A Pending CN103102284A (zh) | 2011-11-09 | 2011-11-09 | 4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103102284A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103965075A (zh) * | 2014-04-04 | 2014-08-06 | 江苏科技大学 | 一类微管蛋白抑制剂及其合成方法和应用 |
CN113214087A (zh) * | 2021-05-06 | 2021-08-06 | 山东科加工业技术研究院有限公司 | 一种4-氯-3,5-二硝基-三氟甲苯的制备方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008242A2 (en) * | 1994-09-16 | 1996-03-21 | Children's Medical Center Corporation | Clotrimazole metabolites in the treatment of sickle cell disease |
CN101698651A (zh) * | 2009-10-23 | 2010-04-28 | 南京大学中国医药城研发中心 | 水杨酰苯胺类衍生物及其制法与用途 |
-
2011
- 2011-11-09 CN CN2011103513424A patent/CN103102284A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008242A2 (en) * | 1994-09-16 | 1996-03-21 | Children's Medical Center Corporation | Clotrimazole metabolites in the treatment of sickle cell disease |
CN101698651A (zh) * | 2009-10-23 | 2010-04-28 | 南京大学中国医药城研发中心 | 水杨酰苯胺类衍生物及其制法与用途 |
Non-Patent Citations (2)
Title |
---|
ARMANDO ROSSELLO等: "Synthesis, Antifungal Activity, and Molecular Modeling Studies of New Inverted Oxime Ethers of Oxiconazole", 《J. MED. CHEM.》 * |
ARZU KARAKURT等: "Synthesis of some 1-(2-naphthyl)-2-(imidazole-1-yl)ethanone oxime and oxime ether derivatives and their anticonvulsant and antimicrobial activities", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103965075A (zh) * | 2014-04-04 | 2014-08-06 | 江苏科技大学 | 一类微管蛋白抑制剂及其合成方法和应用 |
CN113214087A (zh) * | 2021-05-06 | 2021-08-06 | 山东科加工业技术研究院有限公司 | 一种4-氯-3,5-二硝基-三氟甲苯的制备方法及其应用 |
CN113214087B (zh) * | 2021-05-06 | 2022-11-01 | 山东科加工业技术研究院有限公司 | 一种4-氯-3,5-二硝基-三氟甲苯的制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105669565B (zh) | 异长叶烷基嘧啶类化合物及其制备方法与应用 | |
EP3567043B1 (en) | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer | |
CN102863376A (zh) | N-取代甲基-3,5-双取代苄叉基-4-哌啶酮及制备和应用 | |
CN102617391B (zh) | 一种白藜芦醇苯丙烯酰胺类衍生物、其制备方法及其用途 | |
CN103059030A (zh) | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 | |
Mallikanti et al. | Synthesis, antimicrobial activity and molecular docking of novel benzimidazole conjugated 1, 2, 3-triazole analogues | |
CN104230889A (zh) | 环丙沙星衍生物及其制备方法与用途 | |
CN102993093A (zh) | N,n’-二取代二苯基硫脲类化合物、其制备方法和用途 | |
CN103102284A (zh) | 4-三氟甲基-2,6-二硝基苯水杨醛肟类衍生物的制备及其在抗癌治疗药物中的应用 | |
CN103664786A (zh) | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN103086972A (zh) | 吡唑-酰腙类化合物的制备及其在抗癌治疗中的应用 | |
CN102675205B (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN103435560B (zh) | 一类带柔性侧链的苊并[1,2-b]喹喔啉衍生物的合成及其应用 | |
CN102838515A (zh) | 肉桂酰磺酰胺类化合物的制备及其在抗癌治疗药物中的应用 | |
CN104771392A (zh) | 一类组蛋白去乙酰化酶抑制剂及应用 | |
CN104876916A (zh) | 苯醚甲环唑的制备方法 | |
CN109516926A (zh) | 一种荜茇明碱衍生物的制备与抗肿瘤活性 | |
CN103804303B (zh) | Egfr小分子抑制剂嘧啶衍生物及其制备方法与用途 | |
CN103450181B (zh) | 2-[4-(喹喔啉-2-氧基)苯氧基]酰胺的医药用途 | |
CN105461723A (zh) | 酞嗪并[1,2,b]喹唑啉-8-酮化合物及其制备方法和在抗肿瘤药物中的应用 | |
CN104829534A (zh) | 一类含萘环骨架的二氢吡唑吗啉衍生物的制备方法及在抗癌药物中的应用 | |
CN105523961B (zh) | 一类含肉桂酰腙骨架的多甲氧基的抗肿瘤化合物的设计、合成及生物活性评价 | |
CN104817489A (zh) | 一种具有抗肿瘤活性的杂环联苯芳基脲类化合物及其制备方法和应用 | |
CN115583922B (zh) | 含氟n-(3-(苯并噁唑-2-基)苯基)酰胺类化合物及其制备方法和应用 | |
CN103709146B (zh) | 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130515 |